
STAT Plus: Novartis data set up multibillion-dollar battle over breast cancer drugs
The success of the trial of Kisqali, a CDK 4/6 inhibitor, could set up one of the biggest marketing battles in cancer.
Read The StoryInside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
The success of the trial of Kisqali, a CDK 4/6 inhibitor, could set up one of the biggest marketing battles in cancer.
Read The StoryRisk-reward parity says expected returns on investments should be commensurate with the risks. That's not the case for biopharma investing.
Read The StoryRich Pazdur, the director of the FDA Oncology Center of Excellence, addressed rapid approvals, diversity in clinical trials, and more.
Read The Storyadvertisement